Trump signs psychedelics executive order: what it means for the psilocybin, CBD and hemp markets

How a podcaster changed White House policy—and why it matters for everyone working in alternative substances.

On April 18, 2026, something happened in the Oval Office that would have seemed impossible just a few years ago. US President Donald Trump signed an executive order requiring the FDA to expedite clinical trials of psychedelic substances—psilocybin, ibogaine, MDMA, and LSD. Joe Rogan stood nearby. The same Rogan who had been talking about psychedelics on his podcast for years while most politicians pretended the topic didn't exist.

Trump simply said, "Joe wrote to me. I checked. Everyone gave the same answer." And he signed.

This isn't just news about American domestic politics. It's a signal that's already changing the mood of investors, researchers, and markets around the world—including the niches where you operate.

What Exactly Did Trump Sign – and What Does It Really Mean?

The decree does not legalize psychedelics. It's important to understand this difference upfront to avoid false expectations.

Psilocybin and ibogaine remain Schedule I drugs under US law—officially, they are "without recognized medical use and have a high potential for abuse." But the order makes several specific changes that significantly change the rules of the game.

First, the FDA received a directive to issue priority review vouchers to three psychedelic substances the week following the signing. This is the first time in history that the agency has offered an expedited track for any psychedelic. Previously, the full approval cycle took years; now, it's a matter of weeks.

Secondly, the decree allows the use of psychedelics through a "right-to-try" mechanism—a law allowing terminally ill patients to access experimental drugs outside of standard regulatory pathways. This opens the door to true clinical implementation even before formal approval.

Third, and this is the most interesting for the market, the Department of Health and Human Services is required to allocate at least $50 million to states that are already developing or implementing psychedelic programs for the treatment of serious mental disorders. Texas launched its $50 million program back in 2025. Now others will follow suit.

Rogan, Ibogaine, and Veterans: How It All Began

To understand why this happened now, we need to rewind a little.

Ibogaine is a psychoactive compound derived from the African shrub Tabernanthe iboga. It has been used in traditional medicine among the peoples of Central Africa for hundreds of years. In the 1960s, American scientists became interested in it as a treatment for opioid addiction, but research was quickly curtailed due to its cardiotoxicity and the widespread "psychedelic panic" of the era.

Rogan learned about ibogaine from guests on his podcast, including Brian Hubbard, CEO of the nonprofit Americans for Ibogaine, and former Secretary of Energy Rick Perry. Perry himself underwent ibogaine treatment and publicly described it as a "revolutionary experience." He appeared on Rogan's podcast twice to discuss it.

Millions of people heard these conversations. Rogan wrote to Trump. Trump replied: "Sounds great. Want FDA approval? We'll do it."

From text message to executive order, it takes less than a year. For the American regulatory system, that's the speed of light.

Psilocybin: From 'Hippie Drug' to FDA Priority

Psilocybin, the active ingredient in "magic mushrooms," is no less important in this context than ibogaine, although it is mentioned in the decree in a broader list.

Research in recent years has radically shifted the academic consensus. In 2025, a study published in JAMA showed that a single dose of LSD can alleviate anxiety and depression for several months. Similar results are being recorded for psilocybin – Johns Hopkins University, New York University, and Imperial College London are publishing studies after studies confirming its effectiveness for treatment-resistant depression, addiction, and PTSD.

The U.S. Department of Veterans Affairs is currently participating in at least five psychedelic clinical trials in New York, California, and Oregon. This is no longer fringe science—it's a mainstream medical program with federal funding.

This creates a completely different context for the spore and mycelial culture market. Research demand for Psilocybe cubensis and related species isn't just growing—it's becoming more structured. Legitimate research centers, institute labs, and venture-backed startups are springing up. All of them require source material.

CBD and Hemp: Why the Psychedelics Decree Affects You Too

At first glance, CBD and hemp seeds seem like a separate topic. But this is misleading.

Alternative substance markets don't exist in a vacuum. They move together—driven by regulatory sentiment, media attention, and consumer behavior. When Trump signs an executive order on psilocybin, with the planet's most popular podcaster standing nearby, it instantly impacts how the average person perceives the entire category of "alternative and natural health products."

This is called the regulatory signal effect. And it works both ways.

What exactly is changing for the CBD market?

CBD has undergone its regulatory process earlier. In the US, it has been legal at the federal level since 2018, following the passage of the Farm Bill. In Ukraine, the situation is more complex, but the trend is clear: every 12-18 months, the legal framework becomes more lenient, and public perceptions become more relaxed.

Trump's executive order adds an important element to this process. It publicly normalizes the conversation about botanicals and natural substances as a medical tool—not as entertainment, not as an escape from reality—but as therapy. This is a direct benefit to the CBD industry, which has been struggling for years with the same objection: "they're drugs."

When the US President says on live television, "If this is as effective as people say it is, it will have a huge impact," he unwittingly expands the horizons of what is acceptable for the entire market for natural cannabinoid products.

Search trends are already responding. After the decree was signed, searches for "psilocybin benefits," "ibogaine treatment," and "psychedelic therapy" skyrocketed—and along with them, traditionally, searches for CBD, microdosing, and adaptogens are also on the rise. Consumers who come to read about psilocybin often convert into buyers of CBD products. It's a real behavioral funnel.

Cannabis Seeds: Market Research Gains New Arguments

For the seed segment, the situation is more interesting than it seems.

Cannabis sativa and Psilocybe are completely different plants, but in the regulatory mindset, they have long been lumped together under the label "hazardous substances." Trump's executive order is another nail in the coffin.

This is especially relevant in Ukraine. Industrial hemp is legal, and demand for seeds is steadily growing—among farmers, researchers, and enthusiasts. Every time the topic of hemp and its derivatives makes headlines in the medical field, rather than in the criminal realm, it creates a positive backdrop for the entire sector.

The Psychedelic Market in Numbers: Where We Are Now and Where We're Going

To understand the scale of the changes, it's worth looking at the numbers.

According to analytical agencies, the global psychedelic therapy market was valued at $2.3 billion in 2023. Projections for 2030 range from $7 to $11 billion, depending on the regulatory scenario. Trump's executive order is more than just a medical initiative. It opens a new market with federal approval.

Venture capital has been around for a while now. Compass Pathways, MAPS, and Atai Life Sciences are companies with billion-dollar valuations focused specifically on psilocybin and MDMA. Their stock prices have surged since the executive order was signed. But more important is what's happening at the small and medium-sized business level—where niche stores, online retailers, and specialized suppliers thrive.

Demand for fungal spores for microscopic examination in legal jurisdictions has been steadily growing for three years. After this news, it's growing even faster. People who previously wouldn't even Google this topic are now seeing it in mainstream news, and their curiosity level is lowered.

MDMA and LSD in the decree: the signal is broader than it seems

The fact that the decree included not only ibogaine and psilocybin, but also MDMA and LSD is an important nuance.

Ibogaine is already in the final stages of clinical trials for the treatment of PTSD. MAPS has conducted Phase 3 trials and is awaiting FDA approval. Ibogaine's inclusion in the executive order is a signal that the administration is not stopping with ibogaine.

LSD is a rather unexpected guest on this list. This means the White House is prepared to consider even the most "toxic" substances from a public perception perspective. If rhetoric changes at the level of a presidential decree, the media frame shifts accordingly, and then consumer behavior.

For everyone working in related niches, this means one thing: the window of normalization is opening faster than expected.

Rogan's Role: When the Podcast Is More Important Than the Lobbyists

It's worth dwelling on exactly how this happened, because the mechanism is important.

Joe Rogan is not a pharmaceutical lobbyist. He has no medical training. He doesn't represent any companies. He simply invites interesting people and talks with them at length. But his audience—over 14 million listeners per episode—is the largest media platform in American history.

When Rick Perry appeared in his studio and shared his personal experience with ibogaine, and then Brian Hubbard spoke about veterans for whom the substance literally saved their lives, millions of ordinary Americans heard it. Not through scientific journals, not through pharmaceutical company press releases. But through a two-hour conversation between people.

Rogan wrote to Trump personally. He sent the information. Trump responded within a few hours.

This case demonstrates that in 2026, the shortest path from a fringe scientific topic to a presidential executive order isn't congressional hearings or academic publications. It's a podcast with the right guests and direct access to the decision-maker.

This is a fundamental lesson for the market for other substances. Normalization doesn't happen top-down, through regulators and legislators. It happens bottom-up, through content, through personal stories, through audience trust.

What will change in the next 12-24 months: a realistic forecast

Don't expect psilocybin to hit pharmacy shelves tomorrow. But several specific changes are already underway or will happen soon.

• The FDA has already announced that it will issue priority vouchers to three psychedelics. This means expedited approval, which could take months instead of years. The first official approval of a psychedelic drug in the US is a matter of 2026-2027, not the distant future.
• States will receive $50 million in federal funding to develop their programs. Oregon already legalized psilocybin therapy in 2020 and now has an active network of licensed centers. Colorado followed suit in 2022. At least five or six more states will now join them—the funds have already been distributed.
• Research demand for Psilocybe cultures will explode. Universities, private labs, and startups all require pure, genetically verified cultures for their work. The legal research market for spores in jurisdictions where it is permitted will grow proportionally to the number of new studies.
• The CBD market will see an influx of new consumers—people who were drawn to the topic of "plant-based mental health" by the psychedelic buzz but are looking for something more accessible and understandable right now.
• The hemp seed market is benefiting from a generally warming regulatory climate and growing interest in hemp crops in a scientific context.

Risks to be aware of

An honest article cannot do without its downside.

Ibogaine carries real risks of cardiotoxicity—this isn't a fiction circulated by its opponents. Since the 1990s, more than 30 deaths have been linked to its use. That's why the National Institute on Drug Abuse shut down the study back then. The FDA's fast-track approval process doesn't mean ignoring these risks—it means more rapid research that will either confirm safety or establish clear guidelines for its use.

Psilocybin has been better studied, and its safety profile is significantly clearer—but it is not a neutral substance. Its effectiveness depends on the conditions of use, the person being treated, and the individual's condition.

For the market, this means one thing: growing demand will be accompanied by increased regulatory scrutiny. Those who currently build a reputation on quality, transparency, and a responsible approach will win. Those who try to quickly cash in on hype without a foundation are at risk.

What does this mean for you personally?

If you've been interested in psilocybin, CBD, or other natural health substances for a while—but have been stopped by the feeling that they're in a gray area—now's your moment.

This is no longer underground or a conspiracy theory. It's being discussed at Stanford, funded by the federal budget, and signed off on by the President of the United States. Science has finally caught up with what many have known empirically for years.

Psilocybin is being studied as a treatment for depression, anxiety, and addiction—and the initial results are surprising even skeptics. CBD has long shown consistent results in treating chronic stress, pain, and sleep. This isn't magic—it's biochemistry, finally being properly studied.

If you're just starting to understand the topic, now is the perfect time. Information is growing, the quality of research is improving, and access to proven products is easier than ever. The key is to choose with an understanding of what it is, how it works, and what's right for you right now.

This article is based on open sources: PBS NewsHour, NPR, STAT News, Fox News – April 2026.